Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites

Cancer

Volumn 82, Issue 2, 1998, Pages 309-316

  Essner, Richard ^a   Kuo, Christine T ^a   Wang, Hejing ^b   Wen, Duan R ^b   Turner, Roderick R ^c   Nguyen, Tung ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

Prognosis; Skin cancer; Sun exposure; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SKIN CARCINOMA; SUN EXPOSURE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ADULT; AGE FACTORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOPSY; CHI-SQUARE DISTRIBUTION; COLORING AGENTS; ENVIRONMENTAL EXPOSURE; EXTREMITIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MICE; MIDDLE AGED; MUTATION; ODDS RATIO; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; SKIN NEOPLASMS; SUNLIGHT; SURVIVAL RATE; THORAX; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 0031975083     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<317::AID-CNCR10>3.0.CO;2-1     Document Type: Article

References (43)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Fung CY, Fisher DE. P53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995;13:808-11.
4. Zozler F, Hillebrandt S, Streffer C. Radiation induced G1-block and p53 status in six human cell lines. Radiat Oncol 1995;37:20-28.
5. Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, et al. p53 status predicts survival in breast cancer patients with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
6. Nabeya Y, Loganzo F Jr., Maslak P, Lai L, de Oliveira AR, Schwartz GK, et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995;64:37-46.
7. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093-6.
8. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340:1369-73.
9. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992;52:4799-804.
10. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
11. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-54.
12. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
13. Sober AJ. Solar exposure in the etiology of cutaneous melanoma, Photodermatology 1987;4:23-31.
14. Fitzpatrick TB, Sober AJ. Sunlight and skin cancer. N Engl J Med 1985;313:818-20.
15. Kamb A. Cancer. Sun protection factor p53. Nature 1994;372:730-1.
16. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994;130:1018-21.
17. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR, et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993;55:562-5.
18. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 1993;54:693-9.
19. Akslen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer 1992;52:13-6.
20. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993;15:2235-8.
21. Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofolini P, Palma P, et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993;129:739-43.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Morton DL, Essner R, Kirkwood J, Parker RG. Malignant melanoma. In: Holland JF, Frei E, Bast RC Jr., Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. Volume 4. Baltimore: Williams and Wilkins, 1996:2467-99.
24. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
25. Tormanen VT, Pfeifer GP. Mapping of UV photoproducts within ras proto-oncogenes in UV-irradiated cells: correlation with mutations in human skin cancer. Oncogene 1992;7:1729-36.
26. Van't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9:3114-6.
27. Bae I, Smith ML, Sheikh S, Zhan Q, Scudiero DA, Friend SH, et al. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines. Cancer Res 1996;56: 840-7.
28. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
29. Saenz-Santamaria MC, Mcnutt NS, Bogdany JK, Shea CR. p53 expression is rare in cutaneous melanomas. Am J Dermatopathol 1995;17(4):344-9.
30. Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, et al. Overexpression and mutation of p53 in metastatic malignant melanomas. Int J Cancer 1996;67:313-7.
31. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
32. Talve L, Kainu J, Collan Y, Ekfors T. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract 1996;192:825-33.
33. Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995;133:23-31.
34. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1991;90:4216-20.
35. Essner R, Morton DL. Melanoma. In: Harvey J, Beattie EJ, editors. Cancer surgery. New York: W.B. Saunders Co., 1996:505-20.
36. Essner R, Morton DL. Elective lymph node dissection. In: Lejeune FJ, Chaudhuri PK, Das Gupta TK, editors. Malignant melanoma: medical and surgical management. New York: McGraw-Hill, 1993:205-14.
37. Florenes VA, Holm R, Fodstad O. Accumulation of p53 protein in human malignant melanoma: relationship to clinical outcome. Melanoma Res 1995;5:183-7.
38. McGregor JM, Yu CC, Dublin EA, Barnes DM, Levison DA, MacDonald DM. p53 immunoreactivity in human malignant melanoma and dysplastic nevi. Br J Dermatol 1993;128:606-11.
39. Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J. Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 1995;5:387-92.
40. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
41. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
42. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995;1:1463-9.
43. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995;25:1765-9.